|
Originally published In Press as doi:10.1074/jbc.M205541200 on July 11, 2002
J. Biol. Chem., Vol. 277, Issue 37, 34375-34382, September 13, 2002
Erythropoietin Modulates Calcium Influx through TRPC2*
Xin
Chu ,
Joseph Y.
Cheung §,
Dwayne L.
Barber¶ ,
Lutz
Birnbaumer**,
Lawrence I.
Rothblum ,
Kathleen
Conrad ,
Virginia
Abrasonis ,
Yiu-mo
Chan ,
Richard
Stahl ,
David J.
Carey , and
Barbara A.
Miller  §§
From The Henry Hood Research Program, The Sigfried
and Janet Weis Center for Research, and the Departments of
§ Medicine and  Pediatrics, the
Geisinger Clinic, Danville, Pennsylvania 17822, the ¶ Division of
Cellular and Molecular Biology, Ontario Cancer Institute, Toronto,
Ontario M5G 2M9, Canada, and the ** Division of Intramural
Research, NIEHS, National Institutes of Health,
Research Triangle Park, North Carolina 27709
Received for publication, June 4, 2002, and in revised form, July 9, 2002
 |
ABSTRACT |
Mammalian isoforms of calcium-permeable
Drosophila transient receptor potential channels (TRPC) are
involved in the sustained phase of calcium entry in nonexcitable cells.
Erythropoietin (Epo) stimulates a rise in intracellular calcium
([Ca]i) via activation of voltage-independent calcium
channel(s) in erythroid cells. Here, involvement of murine orthologs of
classical TRPC in the Epo-modulated increase in [Ca]i was
examined. RT-PCR of TRPC 1-6 revealed high expression of only TRPC2 in
Epo-dependent cell lines HCD-57 and Ba/F3 Epo-R, in which
Epo stimulates a rise in [Ca]i. Using RT-PCR, Western
blotting, and immunolocalization, expression of the longest isoform of
mTRPC2, clone 14, was demonstrated in HCD-57 cells, Ba/F3 Epo-R cells,
and primary murine erythroblasts. To determine whether erythropoietin
is capable of modulating calcium influx through TRPC2, CHO cells were
cotransfected with Epo-R subcloned into pTracer-CMV and either murine
TRPC2 clone 14 or TRPC6, a negative control, into pQBI50. Successful
transfection of Epo-R was verified in single cells by detection of
green fluorescent protein from pTracer-CMV using digital video imaging,
and successful transfection of TRPC was confirmed by detection of blue
fluorescent protein fused through a flexible linker to TRPC.
[Ca]i changes were simultaneously monitored in cells loaded
with Rhod-2 or Fura Red. Epo stimulation of CHO cells cotransfected
with Epo-R and TRPC2 resulted in a rise in [Ca]i above base
line (372 ± 71%), which was significantly greater
(p 0.0007) than that seen in cells transfected with
TRPC6 or empty pQBI50 vector. This rise in [Ca]i required Epo
and extracellular calcium. These results identify a calcium-permeable
channel, TRPC2, in erythroid cells and demonstrate modulation of
calcium influx through this channel by erythropoietin.
 |
INTRODUCTION |
Erythropoietin (Epo)1 is a hematopoietic growth factor
that regulates proliferation,
differentiation, and viability of erythroid progenitors and precursors
(1-3). Regulation of intracellular calcium ([Ca]i) by
erythropoietin is one of the signaling mechanisms controlling
proliferation and differentiation of erythroid cells (4-10). Evidence
implicating calcium in control of erythroid growth and differentiation
includes: (a) enhancement of Epo-induced murine erythroid
colony growth by the ionophore A23187 and inhibition by treatment with
EGTA, a nonspecific chelator of calcium (7); (b)
demonstration that an increase in Ca2+ influx is an early
and necessary step in the commitment to differentiation of murine
erythroleukemia cells (8-10); and (c) the significant rise
in [Ca]i stimulated by Epo observed at specific stages of
human BFU-E differentiation (5). Substantial evidence supports the
conclusion that erythropoietin stimulates calcium influx in erythroid
cells through voltage-independent calcium-permeable channel(s) (8, 10,
11-13). In patch clamp studies of human erythroid progenitor-derived
cells, Epo stimulation increased calcium channel mean open time
2.5-fold and open probability 10-fold (13).
Recently, the ability of erythropoietin to activate calcium influx and
influence cell proliferation and viability via stimulation of its
receptor (Epo-R) in nonerythroid cells has also been demonstrated. Myoblasts have been shown to express Epo-R, and Epo stimulates myoblast
proliferation to expand the progenitor population during differentiation (14). In these cells, Epo stimulated an increase in
[Ca]i that was entirely dependent on extracellular calcium
influx. Erythropoietin receptors have also been identified on neuronal
cell lines and Epo stimulated calcium influx in these cells as well
(15). Other studies have demonstrated an important neuroprotective and
neurotropic effect of erythropoietin on brain tissue (16-20). Epo
stimulated an increase in cell viability in nerve growth
factor-deprived cells, as well as increases in
45Ca2+ uptake and [Ca]i. These
effects were inhibited by nicardipine, suggesting that Epo may
stimulate neuronal function and viability through activation of calcium
channels (19). These studies suggest a broader role for Epo as a growth
factor capable of maintaining proliferation and preventing apoptosis
during differentiation and emphasize the importance of understanding
the mechanism of erythropoietin regulation of calcium influx.
A major impediment in determining the mechanisms through which
erythropoietin modulates calcium entry and understanding the impact of
this on cell growth and differentiation has been the difficulty in
identifying and cloning the calcium-permeable channel(s) involved.
Recently, a transient receptor potential (TRP) protein superfamily was
identified, consisting of a diverse group of calcium-permeable cation
channels expressed in nonexcitable cells, based on the archetypal TRP
cloned in Drosophila (21, 22). Drosophila TRP is
predominantly expressed in the visual system, is required for phototransduction, and is coupled via a G protein to phospholipase C. Based on sequences from Drosophila TRP, a large number of
mammalian isoforms have been cloned, which have been divided into six
subfamilies (22). All mammalian isoforms share six putative
transmembrane domains similar to the core structure of many
pore-forming subunits of voltage-gated channels except that they lack
positive charged residues necessary for the voltage sensor. The
classical (22) or short (21) TRP channels (TRPC) were selected for our
initial studies, reported here, because these channels have many
characteristics similar to the voltage-independent, Epo-modulated
calcium-permeable channels identified in human erythroblasts. These
TRPC proteins all contain ankyrin repeat domains, which may be
important in protein/protein interactions, and amino acid sequence
identity greater than 30% in their N terminus but high variability in
their carboxyl-terminal region beyond the conserved TRP domain. This diverse family of channels has both store-operated and
receptor-modulated members, which function through intracellular second
messenger systems (21, 22).
The mechanism of regulation of [Ca]i by erythropoietin has
previously been examined at the single cell level using fluorescence
microscopy coupled to digital video imaging (4, 5, 12, 13, 23). In this
report, we used RT-PCR to determine the expression pattern of TRPC on
murine erythroid cell lines HCD-57 and Ba/F3 Epo-R, in which Epo
stimulates a rise in [Ca]i (23). TRPC2 was the only TRPC
detected in these cells under conditions that identified the presence
of all TRPC in brain. Two of four TRPC2 splice variants were expressed
in these hematopoietic cells. The expression and function of the
longest isoform, TRPC2 clone 14 (24), was examined. Cell fractionation
and immunolocalization using an antibody specific for TRPC2 clone 14 demonstrated plasma membrane expression. The ability of erythropoietin
to modulate calcium influx through TRPC2 was determined using a digital
video imaging system in which single cells that expressed transfected Epo-R were identified by detection of green fluorescent protein (GFP),
cells that express transfected TRPC were identified by detection of
blue fluorescent protein (BFP), and [Ca]i changes were
simultaneously measured by Rhod-2 or Fura Red fluorescence.
 |
EXPERIMENTAL PROCEDURES |
Tissue and Cell Lines--
Tissues were obtained from C57Bl/6
mice, frozen in liquid nitrogen, and kept at 80 °C until use.
Ba/F3 cells stably transfected with wild type murine Epo-R were
cultured in RPMI with 10% FCS, 1 mg/ml G418 (Invitrogen), and
500 pg/ml IL-3. HCD-57 cells (Dr. Sandra Ruscetti) were grown in
Iscove's modified Dulbecco's medium with 30% FCS, 5 × 10 5 M 2-mercaptoethanol, and 0.4 units/ml
Epo. CHO cells were cultured in Dulbecco's modified Eagle's medium
with 10% FCS.
Splenic erythroblasts were obtained by injecting mice with
phenylhydrazine (60 mg/kg) intraperitoneally on days 1 and 2. Mice were
sacrificed on day 5 by cervical dislocation, the spleen was removed,
and a single cell suspension was prepared (25, 26). To isolate
erythroid lineage cells (27), the spleen cell suspension was washed and
labeled with Ter-119 Microbeads (10 µl/1 × 107
cells; Miltenyi Biotech, Auburn, CA). Ter-119+ cells were
selected by magnetic sorting with the VarioMACS (Miltenyi). Wright's staining of the Ter-119+ cell fraction revealed
that greater than 95% of nucleated cells were erythroblasts.
RT-PCR of TRPC in Murine Tissue and Cell Lines--
RNA was
prepared from murine brain, heart, kidney, spleen, Ba-F3 Epo-R, HCD-57,
and CHO cells. cDNA was prepared from RNA using the Superscript
first strand synthesis system (Invitrogen) for RT-PCR. Primers were
designed for each TRPC based on coding sequences, and specificity for
each TRPC primer set was confirmed using the NCBI data base. RT-PCR was
typically performed for 35 cycles (denaturation at 95 °C for 20 s, annealing at 60 °C for 30 s, extension at 72 °C for
45-60 s). The following 5' and 3' primers were used in RT-PCR: mTRPC1,
5' primer (5'-GATTTTGGGAAATTTCTGGGAATG-3') and 3' primer
(5'-TTTATCCTCATGATTTGCTATCA-3'); mTRPC2, 5' primer (5'-GACATGATCCGGTTCATGTTC-3') and 3' primer
(5'-CATCAGCATCATCCTCGATCT-3'); mTRPC3, 5' primer
(5'-GACATATTCAAGTTCATGGTTCTC-3') and 3' primer (5'-
ACATCACTGTCATCCTCGATCTC-3'); mTRPC4, 5' primer
(5'-CTGCAGATATCTCTGGGAAGG-3') and 3' primer
(5'-GCTTTGTTCGAGCAAATTTCC-3'); mTRPC5, 5' primer (5'-GATGATACCAATGACGGCAGTG-3') and 3' primer
(5'-CAGATGCCGGATGCTCAGTGAAG-3'); mTRPC6, 5' primer
(5'-ATGAAGCATTCACAACAGTTGAG-3') and 3' primer (5'-GAAAGGTCTTCGTGACTTCCTGA-3'). To obtain RT-PCR bands to
distinguish each of the mTRPC2 splice variants, the following primers
were used: mTRPC2 , 5' primer
(5'-ACCTTCCTGGTCCCAGTGCCCTATC-3') and 3' primer
(5'-GCAGCTGGGCAATCTCATACAGGTC-3'); mTRPC2 , 5' primer (5'-GAGGCAGAGCTGGAGTTCAAGCATTC-3') and 3' primer
(5'-GCAGCTGGGCAATCTCATACAGGTC-3'); mTRPC2 clone 14, 5' primer
(5'-GCCACCATGCTAATGTCCCGCACTG-3') and 3' primer
(5'-TTTGGGCTTACCACACTGGCTGGAG-3'); mTRPC2 clone 17, 5' primer
(5'-CTGCTGTTGATATTTCTCAAGGACAAG-3') and 3' primer (5'-TCGAGTTG GACAACGATCTCCTTG-3'). Control primers used in RT-PCR were as
follows: 18 S rRNA, 5' primer (5'-GGGGCCCGAAGCGTTTACT-3') and 3'
primer (5'-CCCACGGAATCGAGAAAGAGC-3'); -actin, 5' primer
(5'-GGACCTGACAGACTACCTCATGAA-3') and 3' primer
(5'-CTGCTTGCTGATCCACATCTGC-3').
Generation of Antibody Specific to mTRPC Clone 14--
A rabbit
polyclonal antibody was generated to an epitope in the first 100 amino
acids unique to the N terminus of mTRPC2 clone 14 (LNQNSTDVLESDPRPWLTN,
aa 79-98) and affinity-purified. Specificity of the antibody was
confirmed using in vitro translation products prepared with cDNAs for mTRPC2 clone 14 (24), mTRPC2 clone 17 (24),
and mTRPC6 (28), cloned into pcDNA3. The in vitro
products were prepared with the TNT quick coupled
transcription/translation system (Promega, Madison, WI).
Immunolocalization of TRPC2 Channels in HCD-57 Erythroleukemia
Cells with Anti-mTRPC2 Clone 14 Antibody--
HCD-57 cells (3 × 105 cells/chamber) were placed in each well of Lab-Tek
Permanox Chamber Slides precoated with fibronectin. After 30 min, cells
were washed twice with PBS, fixed in methanol at 20 °C for 10 min,
and permeabilized in 0.5% Triton X-100 in PBS for 5 min. Incubation
for 10 min in 20% normal goat serum preceded staining with primary
antibody (anti-TRPC2 clone 14) for 20 min at room temperature followed
by secondary antibody (FITC donkey anti-rabbit IgG, Jackson
Laboratories, West Grove, PA) for 20 min in the dark. Slides were
stained with DAPI in Vectashield mounting medium (Vector Laboratories,
Burlingame, CA) to visualize DNA. Cells were viewed using a Nikon
Optiphot-2 microscope equipped for epifluorescence. Images were
acquired with an air-cooled CCD SenSys digital camera from Photometrics
(Tucson, AZ) and processed using IPLab and Enhanced Photon Reassignment
software programs obtained from Scanalytics, Inc. (Fairfax, VA).
Immunoblotting of Crude Membrane Preparations--
Cell pellets
from CHO cells nontransfected or transfected with mTRPC2 clone 14 in
pcDNA3 (see below), Ba/F3 Epo-R cells, HCD-57 cells, and
Ter-119+ splenic erythroblasts were removed from storage at
80 °C, and 1 ml of Buffer I (10 mM Tris-HCl, pH 7.4, 1× protease inhibitor mixture) was added. Fresh murine brain, heart,
kidney, and spleen were homogenized with a Dounce homogenizer on ice to
create a cell suspension retaining intact cells (confirmed by
microscopy) and centrifuged, and Buffer I was added to each pellet.
Lysates were sonicated, and an equal volume of Buffer II (10 mM Tris-HCl, pH 7.4, 300 mM KCl, 20% sucrose,
1× protease inhibitor mixture) was added. Cells were then centrifuged
at 10,000 × g for 10 min at 4 °C, and the
supernatant was spun at 100,000 × g for 1 h at 4 °C. Crude membranes were solubilized in buffer containing 62 mM Tris-HCl (pH 6.8), 2% SDS, 10% glycerol. Protein was
quantified using the DC Bio-Rad Protein Assay to analyze diluted
samples. Conditions for SDS-PAGE and Western blotting with ECL were as described previously (23, 29). Electrophoresis was performed on 8%
polyacrylamide gels. After transfer, nitrocellulose membranes were
incubated with anti-TRPC2 clone 14 (1:500) or anti-mEpo-R (sc697;
diluted 1:100; Santa Cruz Biotechnology, Inc., Santa Cruz, CA). Donkey
anti-rabbit horseradish peroxidase-conjugated antibody (1:2000) was
used as the secondary antibody.
Transfection of mEpo-R and mTRPC into CHO Cells--
The
pTracer-CMV vector (Invitrogen) containing an SV40 promoter driving
expression of a GFP gene and a CMV promoter driving expression of
mEpo-R was reported previously (23). TRPC2 clone 14 (24), TRPC2 clone
17 (24), and mTRPC6 (28) in pcDNA3 were subcloned into pQBI50
(QbioGene, Carlsbad, CA). The pQBI50 vector contains a CMV promoter,
which drives expression of SuperGlo BFP fused through a flexible linker
to TRPC2 or TRPC6. CHO cells at 50% confluence were transfected with
pTracer-CMV vector (3 µg/ml), pQBI50 vector (3 µg/ml), and
LipofectAMINE (8 µl/ml; Invitrogen) in Opti-MEM 1 for 5 h at
37 °C. One ml was added to each 35-mm dish. At 5 h, an equal
volume of Dulbecco's modified Eagle's medium with 20% FCS was added,
and 18 h later this medium was replaced with Dulbecco's modified
Eagle's medium with 10% FCS. Successful transfection of CHO cells
with Epo-R and TRPC was verified by detection of GFP (excitation, 478 nm; emission, 535 nm) and BFP (excitation, 380 nm; emission, 435 nm),
respectively, in the cells with digital video imaging (4, 5, 12, 13,
23). The optimal time for expression of pTracer CMV Epo-R and pQBI50
TRPC2 was 48-72 h after transfection, and this time interval was
selected to examine the response of transfected CHO cells to Epo. At
this time, 20-40% of individual CHO cells expressed both GFP and BFP. Successful transfection was also confirmed by Western blotting using
whole cell lysates of nontransfected and transfected CHO cells (23).
Anti-TRPC6 was obtained from Alomone Laboratories (Jerusalem, Israel).
Measurement of [Ca]i with Digital Video Imaging--
A
fluorescence microscopy-coupled digital video imaging system was used
to measure [Ca]i (4, 5, 12, 13, 23). To study changes in
[Ca]i in transfected cells, we were not able to use Fura-2 as
the detection fluorophore because its excitation and emission
wavelengths overlap with those of GFP. Instead, we used the fluorescent
Ca2+ indicators Rhod-2 (Molecular Probes, Inc., Eugene, OR)
(23, 30, 31) and, in later experiments, Fura Red (32, 33). Rhod-2 is a
single wavelength excitation Ca2+ fluorophore (excitation,
540 nm; emission, 600 nm), and its fluorescence intensity is
proportional to [Ca]i, fluorophore concentration, optical
path, and excitation light intensity. The ratio Ft (fluorescence at time t) divided by Fo
(fluorescence at base line) was used to reflect changes in
[Ca]i in Rhod-2-loaded CHO cells. CHO cells were loaded with
Rhod-2 (2 µM, 20 min, 37 °C) and stimulated with
recombinant erythropoietin (2000 units/ml; Amgen). Rhod-2 fluorescence
was measured at base line and at 1, 5, 10, 15, and 20 min after Epo
stimulation. In later experiments, to minimize errors associated with
fluorphore leakage and variation in lamp intensity, we used Fura Red
(excitation, 460 and 490 nm; emission, 600-nm long pass) (32,
33), a dual wavelength excitation probe whose fluorescence intensity
ratio is related to [Ca]i. In these experiments, transfected CHO cells were loaded with 5 µM Fura Red-AM, in the
presence of Pluronic F-127 to enhance loading, for 30 min at 37 °C.
Epifluorescence collected at 460-nm excitation was divided by that
collected at 490-nm excitation to obtain the fluorescence intensity
ratio, which was measured at base line and over a 20-min interval as described for Rhod-2. In some experiments, cells were incubated immediately prior to and during Epo stimulation with PBS containing 0.5 mM probenecid (Sigma) to block fluorophore exit from the
cell. [Ca]i measurements were performed in PBS either with (0.7 mM) or without external calcium (2 mM EGTA).
 |
RESULTS |
Expression of TRPC in Murine Tissues and Erythroid Cell Lines Using
RT-PCR--
The ability of erythropoietin to stimulate calcium influx
in murine erythroid cells and erythroleukemia cell lines has been demonstrated previously (7-11, 23). Here, to explore whether this
influx occurred through the classical TRP channels, the expression of
TRPC1 to -6 was examined in HCD-57 murine erythroleukemia cells and in
Ba/F3 Epo-R cells, a hematopoietic cell line stably transfected with
murine Epo-R and previously shown to respond to Epo with a rise in
[Ca]i (23). Expression was compared with that found in
several other murine tissues, and brain was used as a positive control,
since most TRPC are expressed in the brain. RT-PCR was performed using
RNA isolated from murine brain, heart, kidney, spleen, Ba/F3 Epo-R, and
HCD-57 cells. Results are shown in Fig.
1. TRPC2 mRNA was expressed in Ba/F3
Epo-R cells and in HCD-57 cells. No TRPC2 bands were observed when PCR
was performed without the reverse transcriptase step, demonstrating
that these products did not result from contaminating DNA. The identity
of PCR bands was confirmed by sequencing. In contrast, no expression of
other classical TRPC was detected in these hematopoietic cell lines.

View larger version (43K):
[in this window]
[in a new window]
|
Fig. 1.
RT-PCR of TRPC in Murine Tissues and
Cells. RT-PCR was performed on RNA prepared from murine brain,
heart, kidney, spleen, Ba/F3 Epo-R cells, and HCD-57 cells. Specific
primer sets for each TRPC (TRPC1 to -6) are presented under
"Experimental Procedures." 18 S rRNA primers were used as a
positive control.
|
|
Four splice variants of murine TRPC2 have been cloned: mTRPC2 clone 14 (24) (GenBankTM accession number AF111108), mTRPC2 clone 17 (24) (accession number AF111107), mTRPC2 (34) (accession number
AF230802), and mTRPC2 (34) (accession number AF230803). All of
these isoforms would be detected by the mTRPC2 primer set used for
RT-PCR in Fig. 1. To determine which of these four isoforms are
expressed in Ba/F3 and HCD-57 cells, we performed RT-PCR on RNA from
brain, Ba/F3 Epo-R, and HCD-57 cells using primers that are capable of distinguishing them based either on sequence differences or size of the
PCR product. A schema comparing the cDNAs of the different isoforms
and illustrating the strategy of primer selection is shown in Fig.
2A. The primer nucleotide
sequences are provided under "Experimental Procedures." Results of
RT-PCR are shown in Fig. 2B. RNA for mTRPC2 and for
mTRPC2 clone 14 were found in these hematopoietic cell lines. The
identity of PCR bands was confirmed by DNA sequencing. In contrast,
mTRPC2 and mTRPC2 clone 17 were not detected. An appropriately
sized PCR product for TRPC2 clone 17 was observed with the clone 17 primers when cDNA for TRPC2 clone 17 (24) was used as the template,
demonstrating the ability of this primer set to produce a product when
template was available.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 2.
RT-PCR of mTRPC2 isoforms in murine
hematopoietic cells. A, schema of cDNA for the four
mTRPC2 splice variants , , clone 14, and clone 17. Primer
locations (see "Experimental Procedures") that distinguish each
isoform are indicated by the arrows. Hatched
regions indicate DNA sequences unique to mTRPC2 or clone
17. Presumed ATG start sites, calcium pore regions, and the conserved
TRP motif are indicated. B, RT-PCR was performed on RNA
isolated from murine brain, Ba/F3 Epo-R cells, and HCD-57 cells using
primers specific for each of the four mTRPC2 splice variants. RT-PCR
with -actin primers was performed as a control for RNA
quality.
|
|
Generation of Antibody Specific to mTRPC2 Clone 14--
To further
study the expression and function of the longest mTRPC2 isoform, clone
14, an affinity-purified antibody was generated to an epitope unique to
the N terminus of mTRPC2 clone 14. To characterize antibody
specificity, in vitro translation was performed using
cDNAs for mTRPC2 clone 14, mTRPC2 clone 17, and mTRPC6 cloned into
pcDNA3. Expression of the appropriate proteins was first documented
with 35S incorporation. These results are shown in Fig.
3A. Despite several attempts,
translation of mTRPC2 clone 17 could not be improved, possibly because
of the location of the translation start site of this isoform (Fig.
2A) and/or the absence of a perfect Kozak sequence. In
vitro translation reactions were then prepared without 35S. Western blotting was performed with each of these
in vitro translation products with antibody generated to
mTRPC2 clone 14 (Fig. 3B) or with antibody to mTRPC6 (Fig.
3C). These results demonstrate the specificity of antibody
generated to clone 14.

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 3.
Specificity of mTRPC2 clone 14 antibody.
In vitro translated proteins were prepared using cDNA of
mTRPC2 clone 14, mTRPC2 clone 17, and mTRPC6 in pcDNA3.
A, in vitro translation products were prepared
using 35S-labeled methionine, and equivalent amounts of
each reaction were loaded in each lane. B, Western blot of
in vitro translation products from the same three cDNAs.
These were prepared as in A, except nonlabeled methionine
was used. Blots were probed with anti-mTRPC2 clone 14 and demonstrate
the specificity of this antibody. C, Western blots probed as
described in B were stripped and reprobed with antibody to
mTRPC6. Representative results of two experiments are shown.
|
|
Membrane Localization of mTRPC2 Clone 14 in Hematopoietic Cell
Lines--
To determine whether mTRPC2 is expressed in the plasma
membrane of hematopoietic cell lines, immunolocalization studies were performed with HCD-57 cells using anti-mTRPC2 clone 14. DAPI staining was used to localize DNA. Nonimmune rabbit serum was used as a control
for specificity. Cell staining was visualized by fluorescence microscopy (Fig. 4). Images at different
planes through the cell were deconvolved (Scanalytics software) to
remove out-of-focus contaminating light to generate high resolution
images. Representative results (Fig. 4, c and d)
shown here demonstrate that endogeneous mTRPC2 clone 14 protein is
localized at or in close proximity to the plasma membrane in these
cells.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 4.
Immunofluorescence of HCD-57 cells stained
with mTRPC2 clone 14 antibody. HCD-57 cells fixed to glass slides
were stained with anti-mTRPC2 clone 14 antibody (a-d) or
nonimmune rabbit serum (e-h) as primary antibody and
with FITC-donkey anti-rabbit IgG as secondary antibody. DAPI was used
to stain DNA. Fluorescent cell images for FITC (a and
e), and FITC and DAPI merged (b and f)
are shown. Images were taken at three representative planes for each
cell for FITC flourescence (c and g) or FITC and
DAPI fluorescence merged (d and h). After
deconvolution to remove out-of-focus contaminating light (Scanalytics
software), images clearly demonstrate endogenous mTRPC2 expression at
or in close proximity to the plasma membrane.
|
|
To confirm the localization of mTRPC2 to the plasma membrane, crude
membrane preparations were prepared from nontransfected CHO cells,
mTRPC2 clone 14-transfected CHO cells, Ba/F3 Epo-R cells, and HCD-57
cells. To examine the physiological relevance of mTRPC2 clone 14 expression in the Epo-modulated calcium increase in primary erythroid
cells, membranes were also prepared from Ter-119+
erythroblasts isolated from the spleens of phenylhydrazine-treated mice. Preliminary studies revealed that Epo stimulates a rise in
calcium in these cells (data not shown). Western blotting was performed
with protein isolated in the 100,000 × g pellet or
supernatant. A protein band of ~135 kDa was observed in membrane
pellets from mTRPC2 clone 14-transfected CHO cells,
Ter-119+ erythroblasts, Ba/F3 Epo-R cells, and HCD-57 cells
(Fig. 5A), whereas no
equivalent band was observed in nontransfected CHO cells. The quality
of our preparations was demonstrated by reprobing blots with antibody
to murine Epo-R. Epo-R was predominantly observed in the membrane
fraction in Ba/F3 Epo-R cells, HCD-57 cells, and Ter-119+
erythroblasts (Fig. 5A). The different molecular weight
bands observed for mEpo-R probably result from differential
phosphorylation, since HCD-57 cells were grown in the presence of Epo,
which would result in a phosphorylated Epo-R, but Ba/F3 Epo-R cells
were cultured in IL-3 and Ter-119+ cells were removed from
Epo for several hours during the separation procedure. These studies
confirm the membrane localization of mTRPC2 clone 14 and Epo-R in
erythroid cells.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 5.
Membrane localization of mTRPC2 clone
14. A, Western blotting was performed on membranes
prepared from nontransfected CHO, CHO cells transfected with mTRPC2
clone 14 in pcDNA3, Ter-119+ splenic erythroblasts,
Ba/F3 Epo-R cells, and HCD-57 cells as described under "Experimental
Procedures." From the 100,000 × g pellet, 50 µg of
membrane prepared from CHO cells and Ter-119+ erythroblasts
(limited quantity) and 150 µg of membrane from Ba/F3 Epo-R and HCD-57
cells were loaded on each lane. Western blotting was performed with
anti-TRPC2 clone 14 antibody, and blots were then stripped and reprobed
with antibody to Epo-R. The approximate molecular masses (kDa) of
mTRPC2 clone 14 and mEPO-R bands are shown on the right of
the blot. B, Western blotting was performed on membranes
prepared from CHO cells transfected with mTRPC2 clone 14; murine brain,
heart, kidney, spleen, and Ba/F3 Epo-R; and HCD-57 cells as
controls. Fifty µg of membrane prepared from CHO cells and 150 µg
of membrane prepared from other tissues were loaded on each lane, and
the blots were detected with antibody to mTRPC2 clone 14.
|
|
To determine whether mTRPC2 clone 14 protein expression is restricted
to specific cell types, we performed Western blotting on membrane
preparations from murine brain, heart, kidney, and spleen (Fig.
5B). No band was detected at 135 kDa in heart, kidney, or
spleen, confirming the restricted expression pattern of this isoform.
In brain, a band was observed at 135 kDa, consistent with RT-PCR
results showing that clone 14 protein is expressed in brain. Two other
bands were consistently observed adjacent to the fainter band at 135 kDa and may represent protein modifications or alternative clone 14 splice variants expressed only in brain. A light exposure is shown in
Fig. 5B to clearly show the distribution of bands found in
the membrane of murine brain.
Transfection of CHO Cells with pTracer-CMV Epo-R and pQBI50 mTRPC2
Clone 14--
To determine whether Epo is capable of regulating
calcium influx through mTRPC2, we established a system in which single
cells transfected with wild type Epo-R could be identified by GFP
fluorescence, cells transfected with mTRPC2 could be identified by BFP
fluorescence, and [Ca]i could be measured simultaneously in
the identical cells with digital video imaging. CHO cells were used for
these transfections, because they lack endogenous Epo-R and have been shown to contain all of the necessary transducers required for a modest
growth factor- and Epo-induced [Ca]i increase (23, 35). In
Fig. 6, nine CHO cells are shown 48 h after cotransfection with Epo-R and full-length mTRPC2 clone 14 (Fig.
6A). Three CHO cells successfully transfected with Epo-R
were detected by GFP fluorescence (Fig. 6B). The same three
CHO cells also showed BFP fluorescence, indicating successful
transfection with mTRPC2 (Fig. 6C). [Ca]i was
measured in the same representative cells (indicated by the
arrows) with Rhod-2 fluorescence (Fig. 6D). No
interference by GFP/BFP was detected under conditions for Rhod-2 or
Fura Red (see below) fluorescence measurements.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 6.
Detection of GFP, BFP, and Rhod-2 in CHO
cells transfected with pTracer-CMV Epo-R and pQBI50 mTRPC2 c14.
A, white light image of CHO cells. B, successful
transfection of CHO cells with pTracer-CMV Epo-R expressing GFP
(excitation, 478 nm; emission, 535 nm). C, three cells were
also successfully transfected with BFP-mTRPC2 (excitation, 380 nm;
emission, 435 nm). D, Rhod-2 fluorescence of the same CHO
cells (excitation, 540 nm; emission, 600 nm). Representative cells in
which calcium was measured are indicated by arrows.
|
|
Expression of transfected mTRPC in CHO cells was further confirmed by
immunoblotting. Cell lysates from nontransfected CHO cells or CHO cells
transfected with mTRPC2 clone 14 or mTRPC6 were prepared. Western
blotting was performed with antibody to mTRPC2 clone 14, and blots were
stripped and reprobed with antibody to mTRPC6. Results confirming
expression are shown in Fig. 7. The
higher molecular weight of both proteins shown here compared with that
in reticulocyte lysates (prepared from pcDNA3; Fig. 3) or crude
membrane fractions (Fig. 5) is a result of linkage to BFP. These
results also confirm that CHO cells express undetectable amounts of
TRPC2 clone 14 or TRPC6 orthologs or that the TRPC antibodies fail to
cross-react with the hamster TRPC proteins.

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 7.
Western blot of transfected CHO cells.
Lysates were prepared from nontransfected ( ) CHO cells or CHO cells
transfected with BFP-tagged TRPC2 clone 14 or TRPC6 in pQBI50. Fifty
µg of protein was loaded in each lane. Western blotting was performed
with anti-mTRPC2 c14 or anti-mTRPC6 antibodies, followed by ECL.
|
|
Response of CHO Cells Transfected with Epo-R and mTRPC2 to
Epo--
CHO cells were cotransfected with Epo-R and mTRPC2 clone 14 for 48-72 h. Other CHO cells were cotransfected with Epo-R and empty
pQBI50 vector or vector subcloned with mTRPC6 as controls. [Ca]i in cells loaded with Rhod-2 was measured before and at
intervals for 20 min after Epo stimulation. Results are shown in Table
I. Epo stimulation of CHO cells
transfected with Epo-R and empty pQBI50 vector demonstrated a modest
increase in [Ca]i above base line (137 ± 18%),
consistent with our previous observations (23). Epo stimulation of CHO
cells cotransfected with Epo-R and mTRPC2 clone 14 resulted in a much
larger rise in [Ca]i above base line (372 ± 71%),
which was significantly (p 0.0007) greater than that
seen in cells cotransfected with mTRPC6 or empty pQBI50 vector. No
increase in [Ca]i was seen when CHO cells cotransfected with
Epo-R and TRPC2 were stimulated with diluent (PBS), demonstrating the
specificity of the Epo response. In cells cotransfected with Epo-R and
mTRPC6, which was not found in murine hematopoietic cell lines, the
increase in [Ca]i in response to Epo was not statistically
different from that observed in cells transfected with Epo-R and empty
pQBI50 vector.
View this table:
[in this window]
[in a new window]
|
Table I
Response to Epo of CHO cells transfected with Epo-R and TRPC2
CHO cells were cotransfected with pTracer-CMV mEpo-R and with empty
pQBI50 vector, mTRPC2 clone 14 subcloned into pQBI50, or mTRPC6
subcloned into pQBI50. Fo in Rhod-2-loaded cells was
measured before Epo stimulation, and Ft was measured
at 1, 2.5, 5, 10, 15, and 20 min after Epo stimulation (10 units/ml).
Mean Fo, peak Ft, and the
percentage increase of Ft/Fo ± S.E. are shown. Ft/Fo,
fluorescence at time t/fluorescence at time 0; n,
number of cells studied.
|
|
To further confirm results, experiments were performed in the presence
of 0.5 mM probenecid to minimize fluorophore exit from cells. CHO cells cotransfected with Epo-R and mTRPC2 clone 14 or mTRPC6
were loaded with Rhod-2. [Ca]i values before and after Epo
stimulation are shown in Table II. The
significant increase in [Ca]i observed in mTRPC2-transfected
cells was maintained and amplified.
View this table:
[in this window]
[in a new window]
|
Table II
Response to Epo of CHO cells transfected with Epo-R and mTRPC2 in the
presence of probenecid
CHO cells were cotransfected with pTracer-CMV mEpo-R and with empty
pQBI50 vector, mTRPC2 clone 14 subcloned into pQBI50, and mTRPC6
subcloned into pQBI50. Fo in Rhod-2-loaded cells was
measured before Epo stimulation and Ft at intervals
over 20 min after Epo stimulation (10 units/ml) in the presence of 0.5 mM probenecid. Mean Fo, peak
Ft, and percentage increase of
Ft/Fo ± S.E. are shown.
Ft/Fo, fluorescence at time
t/fluorescence at time 0; n, number of cells
studied.
|
|
To confirm that the [Ca]i increase in response to
erythropoietin in transfected CHO cells originated from external calcium influx rather than internal store release, CHO cells
transfected with Epo-R and TRPC2 clone 14 were stimulated by Epo in the
presence of calcium (0.7 mM) or its absence (2 mM EGTA). [Ca]i was measured over 20 min in Fura
Red-loaded cells (Fig. 8). No change in
[Ca]i of Epo-stimulated cells was observed over 20 min in the
absence of extracellular calcium. However, when calcium chloride (3 mM) was added at 10 min, there was a prompt and significant
increase (p 0.01) in [Ca]i in cells
treated with erythropoietin at time 0. The addition of exogenous calcium to doubly transfected CHO cells not treated with erythropoietin did not increase [Ca]i. These results indicate that
erythropoietin primes the calcium influx pathway through TRPC2, which
remained open so that when extracellular free calcium was made
available, [Ca]i increased promptly. In other experiments
designed to detect Ca2+ release from internal stores in
response to Epo, [Ca]i was measured at 30-s intervals for the
first 2 min after Epo addition, but no increase in [Ca]i was
detected.

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 8.
Requirement for Epo and external calcium in
the Epo-stimulated calcium increase in transfected CHO cells. Fura
Red-loaded CHO cells transfected with pTracer-CMV Epo-R and pQBI50
mTRPC2 c14 in 2 mM EGTA were treated with Epo (10 units/ml)
or PBS (vehicle) at 0 min. Exogeneous calcium chloride (3 mM) was added where indicated at 10 min. The mean
percentage change ± S.E. in the fluorescence intensity ratio at
each time point compared with base line is shown.
|
|
 |
DISCUSSION |
In this report, CHO cells were transfected with wild-type Epo-R
and with specific TRPC channels to study erythropoietin signal transduction involving calcium channel activation. This is the first
study of receptor-mediated calcium signaling in which successful transfection of both receptor and putative calcium channel were authenticated at the single cell level by fluorescence from different fluorophores, GFP and BFP, and [Ca]i modulation was studied with a third fluorophore, Rhod-2 or Fura Red. This method can be
generalized to many receptor/channel systems.
The first major finding of the present study is that TRPC2 mRNA and
protein are expressed on hematopoietic cells. Using three independent
approaches, RT-PCR, Western blotting, and immunolocalization, we
demonstrated that a classical TRP channel, mTRPC2, is expressed in
murine hematopoietic cells. Four TRPC2 splice variants have been
reported: mTRPC2 clone 14 (131 kDa) (24), mTRPC2 clone 17 (116 kDa)
(24), mTRPC2 (99 kDa) (34), and mTRPC2 (100 kDa) (34). Their
tissue distribution and function has been controversial (24, 34,
36-38). High expression of mTRPC2 in testis, sperm, and VNO has
been reported (24, 36, 38), but the presence of expressed sequence tags
derived from TRPC2 mRNA in kidney (GenBankTM accession
number AA473022) and spleen (GenBankTM accession number
AA145678) suggests that mTRPC2 may be present in many other tissues but
at low levels. Here, using RT-PCR specific for each of the known mTRPC2
isoforms, we identified expression of mTRPC2 and mTRPC2 clone 14 but not mTRPC2 or clone 17 in murine hematopoietic cells. In
addition, using a newly characterized antibody specific to the longest
TRPC2 isoform, clone 14, we were able to confirm the presence of TRPC2
protein. Our results may differ from previous reports because of the
technique (RT-PCR) utilized. Our studies support the possibility that
mTRPC2 clone 14 protein expression is restricted to certain cell types
including hematopoietic cells and brain. The plasma membrane
localization of mTRPC2 in hematopoietic cells is consistent with
current and previous functional results (24, 36), which require
membrane localization of mTRPC2 for calcium influx. Liman et
al. (38) also localized rat TRPC2 to the microvillar plasma
membrane of VNO receptor neurons.
Erythropoietin has previously been shown to modulate
voltage-independent calcium channel(s) (8, 12, 13, 23). The second
major finding is that Epo is capable of modulating calcium influx
through TRPC2. Epo, external calcium, TRPC2, and Epo-R are all required
for a calcium rise in our CHO cell model system (Fig. 8, Tables I and
II) (23) comparable with that seen in human BFU-E-derived cells
stimulated with Epo, demonstrating the specificity of this response.
Because Epo stimulates an increase in calcium in Ba/F3 Epo-R cells (23)
and in Ter-119+ erythroblasts (data not shown) in which
both TRPC2 and Epo-R are expressed on the plasma membrane, these data
demonstrate that TRPC2 is a physiologically relevant candidate for
mediating the Epo-stimulated [Ca]i increase (4-11). In
nontransfected CHO cells, we were unable to detect expression of TRPC2
or TRPC6 with either RT-PCR (data not shown) or Western blotting,
indicating that CHO cells constitute a good model system to study the
interaction between Epo-R and TRPC channels. In addition, the large
Epo-stimulated increase in [Ca]i (>300%) observed in
TRPC2-transfected CHO cells, when compared with that observed in cells
transfected with TRPC6 or BFP vector alone, is reminiscent of the
magnitude (300-400%) of the Epo-induced [Ca]i increase in
human BFU-E-derived erythroblasts (5, 12). In previous studies involving CHO cells transfected with Epo-R only (23), the magnitude of
Epo-stimulated increase in [Ca]i was quite modest (<150%),
suggesting that either TRPC2 in CHO cells is present in very small
amounts not detectable by our RT-PCR conditions or that endogenous
Ca2+-permeable channels in CHO cells and erythroid cells
are different.
TRPC2 has been reported to be activated by both calcium store release
(24, 36) and receptor-operated mechanisms, including activation by the
M5 muscarinic receptor (24) and in sperm by the glycoprotein ZP3 in the
egg's extracellular matrix (36). TRPC2 has also been shown to have a
very important function in rodent pheromone receptor activation in the
VNO (37), through a mechanism postulated to involve phospholipase C but
not calcium store release, since VNO lack calcium stores (38). Although the mechanisms by which Epo regulates TRPC2 activity were not addressed
in this exploratory study, in erythroid cells, we were unable to
demonstrate an increase in [Ca]i in the first 2 min after Epo
stimulation, arguing against activation of TRPC by depletion of calcium
stores in these cells. Of note, two other TRP family channels have also
been shown to be regulated by growth factors: (a) GRC, a
mouse homologue of VRL-1, by insulin-like growth factor-1 through
regulation of membrane trafficking (39) and (b) TRPC3 by
brain-derived nerve growth factor through activation of the
neurotrophin receptor TrkB and phospholipase C (40).
In summary, we have shown plasma membrane expression of both mTRPC2
clone 14 and Epo-R in erythroid cells. Using CHO cells doubly
transfected with Epo-R and TRPC channels, we demonstrated the ability
of Epo-R to regulate calcium influx through mTRPC2 but not mTRPC6.
Whereas our data clearly demonstrate a role for mTRPC2, it is probably
not the only TRP channel of importance in hematopoietic cells. LTRPC2
is expressed on hematopoietic cells, has an important role in calcium
influx in immunocytes, and is involved in tumor necrosis
factor- -induced cell death (41, 42). Sequence homology analysis
using the Kimura pairwise near neighbor approach has placed mTRPC2 near
the TRPM family channels LTRPC1 and LTRPC2 (24). Several TRP channels
have been shown to form heteromultimers in vivo (22, 43,
44). LTRPC2 is a candidate calcium channel for regulation by
hematopoietic growth factors and for interaction with mTRPC2. Important
challenges will be to identify the other TRP channels expressed on
hematopoietic cells, including ones that have not yet been cloned, and
to determine the regulation and function of TRP homo- and
heteromultimeric channels in hematopoietic growth factor-regulated
proliferation, differentiation, and cell survival.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grants DK 46778 (to B. A. M), HL 58672 (to J. Y. C.), GM 46991 (to L. I. R.), and NS 21925, NS 37716, and NS 41363 (to D. J. C.) and
grants from the Geisinger Foundation (to B. A. M., J. Y. C., L. I. R., Y. C., and D. J. C.).The costs of publication of this article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Research Scientist of the National Cancer Institute of Canada.
§§
To whom correspondence should be addressed: The Henry Hood
Research Program, The Sigfried and Janet Weis Center for Research, Geisinger Clinic, 100 N. Academy Ave., Danville, PA 17822-2616. Tel.:
570-271-6675; Fax: 570-271-6701; E-Mail:
bamiller1{at}geisinger.edu.
Published, JBC Papers in Press, July 11, 2002, DOI 10.1074/jbc.M205541200
 |
ABBREVIATIONS |
The abbreviations used are:
Epo, erythropoietin;
TRP, transient receptor potential;
GFP, green fluorescent protein;
BFP, blue fluorescent protein;
FCS, fetal calf serum;
CHO, Chinese hamster
ovary;
PBS, phosphate-buffered saline;
FITC, fluorescein
isothiocyanate;
DAPI, 4',6-diamidino-2-phenylindole;
CMV, cytomegalovirus;
VNO, vomeronasal organ.
 |
REFERENCES |
| 1.
|
Damen, J. E.,
and Krystal, G.
(1996)
Exp. Hematol.
24,
1455-1459[Medline]
[Order article via Infotrieve]
|
| 2.
|
Wojchowski, D. M.,
Gregory, R. C.,
Miller, C. P.,
Pandit, A. K.,
and Pircher, T. J.
(1999)
Exp. Cell Res.
253,
143-156[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Cheung, J. Y.,
and Miller, B. A.
(2001)
Nephron
87,
215-222[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Miller, B. A,
Scaduto, R. C., Jr.,
Tillotson, D. L.,
Botti, J. J.,
and Cheung, J. Y.
(1988)
J. Clin. Invest.
82,
309-315[Medline]
[Order article via Infotrieve]
|
| 5.
|
Miller, B. A.,
Cheung, J. Y.,
Tillotson, D. L.,
Hope, S. M.,
and Scaduto, R. C., Jr.
(1989)
Blood
73,
1188-1194[Abstract/Free Full Text]
|
| 6.
|
Mladenovic, J.,
and Kay, N. E.
(1988)
J. Lab. Clin. Med.
112,
23-27[Medline]
[Order article via Infotrieve]
|
| 7.
|
Misiti, J.,
and Spivak, J. L.
(1979)
J. Clin. Invest.
64,
1573-1579[Medline]
[Order article via Infotrieve]
|
| 8.
|
Gillo, B., Ma, Y.-S.,
and Marks, A. R.
(1993)
Blood
81,
783-792[Abstract/Free Full Text]
|
| 9.
|
Hensold, J. O.,
Dubyak, G.,
and Housman, D. E.
(1991)
Blood
77,
1362-1370[Abstract/Free Full Text]
|
| 10.
|
Levenson, R.,
Housman, D.,
and Cantley, L.
(1980)
Proc. Natl. Acad. Sci. U. S. A.
77,
5948-5952[Abstract/Free Full Text]
|
| 11.
|
Sawyer, S. T.,
and Krantz, S. B.
(1984)
J. Biol. Chem.
259,
2769-2774[Abstract/Free Full Text]
|
| 12.
|
Cheung, J. Y.,
Elensky, M. B.,
Brauneis, U.,
Scaduto, R. C., Jr.,
Bell, L. L.,
Tillotson, D. L.,
and Miller, B. A.
(1992)
J. Clin. Invest.
90,
1850-1856[Medline]
[Order article via Infotrieve]
|
| 13.
|
Cheung, J. Y.,
Zhang, X.-Q.,
Bokvist, K.,
Tillotson, D. L.,
and Miller, B. A.
(1997)
Blood
89,
92-100[Abstract/Free Full Text]
|
| 14.
|
Ogilvie, M., Yu, X.,
Nicolas-Metral, V.,
Pulido, S. M.,
Liu, C.,
Ruegg, U. T.,
and Noguchi, C. T.
(2000)
J. Biol. Chem.
275,
39754-39761[Abstract/Free Full Text]
|
| 15.
|
Masuda, S.,
Nagao, M.,
Takahata, K.,
Konishi, Y.,
Gallyas, F., Jr.,
Tabira, T.,
and Sasaki, R.
(1993)
J. Biol. Chem.
268,
11208-11216[Abstract/Free Full Text]
|
| 16.
|
Dame, C.,
Juul, S. E.,
and Christensen, R. D.
(2001)
Biol. Neonate
79,
228-235[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Cerami, A.,
Brines, M. L.,
Ghezzi, P.,
and Cerami, C. J.
(2001)
Semin. Oncol.
28 Suppl. 8,
66-70[Medline]
[Order article via Infotrieve]
|
| 18.
|
Siren, A.-L.,
Fratelli, M.,
Brines, M.,
Goemans, C.,
Casagrande, S.,
Lewczuk, P.,
Keenan, S.,
Gleiter, C.,
Pasquali, C.,
Capobianco, A.,
Mennini, T.,
Heumann, R.,
Cerami, A.,
Ehrenreich, H.,
and Ghezzi, P.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
4044-4049[Abstract/Free Full Text]
|
| 19.
|
Koshimura, K.,
Murakami, Y.,
Sohiya, M.,
Tanaka, J.,
and Kato, Y.
(1999)
J. Neurochem.
72,
2565-2572[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Ghosh, A.,
and Greenberg, M. E.
(1995)
Science
268,
239-247[Abstract/Free Full Text]
|
| 21.
|
Harteneck, C.,
Plant, T. D.,
and Schultz, G.
(2000)
Trends Neurosci.
23,
159-166[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
| Montell, C. (2001) Science's STKE, 2001(90):RE1
|
| 23.
|
Miller, B. A.,
Barber, D. L.,
Bell, L. L.,
Beattie, B. K.,
Zhang, M.-Y.,
Neel, B. G.,
Yoakim, M.,
Rothblum, L. I.,
and Cheung, J. Y.
(1999)
J. Biol. Chem.
274,
20465-20472[Abstract/Free Full Text]
|
| 24.
|
Vannier, B.,
Peyton, M.,
Boulay, G.,
Brown, D.,
Qin, N.,
Jiang, M.,
Zhu, X.,
and Birnbaumer, L.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
2060-2064[Abstract/Free Full Text]
|
| 25.
|
Barber, D. L.,
Beattie, B. K.,
Mason, J. M.,
Nguyen, M. H.-H.,
Yoakim, M.,
Neel, B.,
D'Andrea, A. D.,
and Frank, D. A.
(2001)
Blood
97,
2230-2237[Abstract/Free Full Text]
|
| 26.
|
Krystal, G.
(1983)
Exp. Hematol.
11,
649-660[Medline]
[Order article via Infotrieve]
|
| 27.
|
Kina, T.,
Ikuta, K.,
Takayama, E.,
Wada, K.,
Majumdar, A. S.,
Weissman, I. L.,
and Katsura, Y.
(2000)
Br. J. Hematol.
109,
280-287[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Zhu, X.,
Jiang, M.,
Peyton, M.,
Boulay, G.,
Hurst, R.,
Stefani, E.,
and Birnbaumer, L.
(1996)
Cell
85,
661-671[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Zhang, M.-Y.,
Harhaj, E. W.,
Bell, L.,
Sun, S.-C.,
and Miller, B. A.
(1998)
Blood
92,
1225-1234[Abstract/Free Full Text]
|
| 30.
|
Mitani, A.,
Takeyasu, S.,
Yanase, H.,
Nakamura, Y.,
and Kataoka, K.
(1994)
J. Neurochem.
62,
626-634[Medline]
[Order article via Infotrieve]
|
| 31.
|
Yoshino, M.,
and Kamiya, H.
(1995)
Brain Res.
695,
179-185[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Wu, Y.,
and Clusin, W. T.
(1997)
Am. J. Physiol.
273,
H2161-H2169[Abstract/Free Full Text]
|
| 33.
|
Kurebayashi, N.,
Harkins, A. B.,
and Baylor, S. M.
(1993)
Biophys. J.
64,
1934-1960[Medline]
[Order article via Infotrieve]
|
| 34.
|
Hofmann, T.,
Schaeffer, M.,
Schultz, G.,
and Gudermann, T.
(2000)
Biochem. J.
351,
115-122[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Billestrup, N.,
Bouchelouche, P.,
Allevato, G.,
Ilondo, M.,
and Nielsen, H.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
2725-2729[Abstract/Free Full Text]
|
| 36.
|
Jungnickel, M. K.,
Marrero, H.,
Birnbaumer, L.,
Lemos, J. R.,
and Florman, H. M.
(2001)
Nat. Cell Biol.
3,
499-502[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Stowers, L.,
Holy, T. E.,
Meister, M.,
Dulac, C.,
and Koentges, G.
(2002)
Science
295,
1493-1500[Abstract/Free Full Text]
|
| 38.
|
Liman, E. R.,
Corey, D. P.,
and Dulac, C.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
5791-5796[Abstract/Free Full Text]
|
| 39.
|
Kanzaki, M.,
Zhang, Y.-Q.,
Mashima, H., Li, L.,
Shibata, H.,
and Kojima, I.
(1999)
Nat. Cell Biol.
1,
165-170[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Li, H. S., Xu, X. Z.,
and Montell, C.
(1999)
Neuron
24,
261-273[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Sano, Y.,
Inamura, K.,
Miyake, A.,
Mochizuki, S.,
Yokoi, H.,
Matsushime, H.,
and Furuichi, K.
(2001)
Science
293,
1327-1330[Abstract/Free Full Text]
|
| 42.
|
Hara, Y.,
Wakamori, M.,
Ishii, M.,
Maeno, E.,
Nishida, M.,
Yoshida, T.,
Yamada, H.,
Shimizu, S.,
Mori, E.,
Kudoh, J.,
Shimizu, N.,
Kurose, H.,
Okada, Y.,
Imoto, K.,
and Mori, Y.
(2002)
Mol. Cell
9,
163-173[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Lintschinger, B.,
Balzer-Geldsetzer, M.,
Baskaran, T.,
Graier, W. F.,
Romanin, C.,
Zhu, M. X.,
and Groschner, K.
(2000)
J. Biol. Chem.
275,
27799-27805[Abstract/Free Full Text]
|
| 44.
|
Strubing, C.,
Krapivinsky, G.,
Krapivinsky, L.,
and Clapham, D. E.
(2001)
Neuron
29,
645-655[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
I. Hirschler-Laszkiewicz, Q. Tong, K. Conrad, W. Zhang, W. W. Flint, A. J. Barber, D. L. Barber, J. Y. Cheung, and B. A. Miller
TRPC3 Activation by Erythropoietin Is Modulated by TRPC6
J. Biol. Chem.,
February 13, 2009;
284(7):
4567 - 4581.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Abramowitz and L. Birnbaumer
Physiology and pathophysiology of canonical transient receptor potential channels
FASEB J,
February 1, 2009;
23(2):
297 - 328.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Hewavitharana, X. Deng, Y. Wang, M. F. Ritchie, G. V. Girish, J. Soboloff, and D. L. Gill
Location and Function of STIM1 in the Activation of Ca2+ Entry Signals
J. Biol. Chem.,
September 19, 2008;
283(38):
26252 - 26262.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q. Tong, I. Hirschler-Laszkiewicz, W. Zhang, K. Conrad, D. W. Neagley, D. L. Barber, J. Y. Cheung, and B. A. Miller
TRPC3 Is the Erythropoietin-regulated Calcium Channel in Human Erythroid Cells
J. Biol. Chem.,
April 18, 2008;
283(16):
10385 - 10395.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Tringali, G. Pozzoli, L. Lisi, and P. Navarra
Erythropoietin Inhibits Basal and Stimulated Corticotropin-Releasing Hormone Release from the Rat Hypothalamus via a Nontranscriptional Mechanism
Endocrinology,
October 1, 2007;
148(10):
4711 - 4715.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Zhang, Q. Tong, K. Conrad, J. Wozney, J. Y. Cheung, and B. A. Miller
Regulation of TRP channel TRPM2 by the tyrosine phosphatase PTPL1
Am J Physiol Cell Physiol,
May 1, 2007;
292(5):
C1746 - C1758.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q. Tong, W. Zhang, K. Conrad, K. Mostoller, J. Y. Cheung, B. Z. Peterson, and B. A. Miller
Regulation of the Transient Receptor Potential Channel TRPM2 by the Ca2+ Sensor Calmodulin
J. Biol. Chem.,
April 7, 2006;
281(14):
9076 - 9085.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Zhang, I. Hirschler-Laszkiewicz, Q. Tong, K. Conrad, S.-C. Sun, L. Penn, D. L. Barber, R. Stahl, D. J. Carey, J. Y. Cheung, et al.
TRPM2 is an ion channel that modulates hematopoietic cell death through activation of caspases and PARP cleavage
Am J Physiol Cell Physiol,
April 1, 2006;
290(4):
C1146 - C1159.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Soboloff, M. Spassova, W. Xu, L.-P. He, N. Cuesta, and D. L. Gill
Role of Endogenous TRPC6 Channels in Ca2+ Signal Generation in A7r5 Smooth Muscle Cells
J. Biol. Chem.,
December 2, 2005;
280(48):
39786 - 39794.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q. Tong, X. Chu, J. Y. Cheung, K. Conrad, R. Stahl, D. L. Barber, G. Mignery, and B. A. Miller
Erythropoietin-modulated calcium influx through TRPC2 is mediated by phospholipase C{gamma} and IP3R
Am J Physiol Cell Physiol,
December 1, 2004;
287(6):
C1667 - C1678.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Mercier, C. Morin, M. Cloutier, S. Proteau, J. Rokach, W. S. Powell, and E. Rousseau
5-Oxo-ETE regulates tone of guinea pig airway smooth muscle via activation of Ca2+ pools and Rho-kinase pathway
Am J Physiol Lung Cell Mol Physiol,
October 1, 2004;
287(4):
L631 - L640.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. J. Parsa, J. Kim, R. U. Riel, L. S. Pascal, R. B. Thompson, J. A. Petrofski, A. Matsumoto, J. S. Stamler, and W. J. Koch
Cardioprotective Effects of Erythropoietin in the Reperfused Ischemic Heart: A POTENTIAL ROLE FOR CARDIAC FIBROBLASTS
J. Biol. Chem.,
May 14, 2004;
279(20):
20655 - 20662.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Chu, Q. Tong, J. Y. Cheung, J. Wozney, K. Conrad, V. Mazack, W. Zhang, R. Stahl, D. L. Barber, and B. A. Miller
Interaction of TRPC2 and TRPC6 in Erythropoietin Modulation of Calcium Influx
J. Biol. Chem.,
March 12, 2004;
279(11):
10514 - 10522.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Ducret, A.-M. Vacher, and P. Vacher
Effects of Prolactin on Ionic Membrane Conductances in the Human Malignant Astrocytoma Cell Line U87-MG
J Neurophysiol,
March 1, 2004;
91(3):
1203 - 1216.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Li, C. Miller, S. Hegde, and D. Wojchowski
Roles for an Epo Receptor Tyr-343 Stat5 Pathway in Proliferative Co-signaling with Kit
J. Biol. Chem.,
October 17, 2003;
278(42):
40702 - 40709.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Cloutier, S. Campbell, N. Basora, S. Proteau, M. D. Payet, and E. Rousseau
20-HETE inotropic effects involve the activation of a nonselective cationic current in airway smooth muscle
Am J Physiol Lung Cell Mol Physiol,
September 1, 2003;
285(3):
L560 - L568.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Zhang, X. Chu, Q. Tong, J. Y. Cheung, K. Conrad, K. Masker, and B. A. Miller
A Novel TRPM2 Isoform Inhibits Calcium Influx and Susceptibility to Cell Death
J. Biol. Chem.,
April 25, 2003;
278(18):
16222 - 16229.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|